FDA Warns Invokana® Users of Bone Fracture Risks
December 8th, 2015|
The U.S. Food and Drug Administration (FDA) approved the drug Invokana® for the treatment of Type II diabetes in 2013. Since being approved, studies have shown the drug can cause serious health problems in some users.
The drug injury lawyers at Ferrer, Poirot & Wansbrough explain one of the most serious adverse effects Invokana can have on users is a condition known as Ketoacidosis. A patient develops Ketoacidosis when the medication causes the levels of certain acids in the blood to reach toxic levels. However, this isn’t the only health problem that has been associated with Invokana.
An article from Diabetes In Control says the FDA recently issued warnings regarding the use of Invokana and the increased risk of suffering bone fractures.
Researchers examined the cases of 714 patients who were taking Invokana during a two-year period. The study concluded that taking Invokana can result in a decrease of bone mineral density, which can lead to bones becoming brittle and more prone to breaking. The risks of bone fractures can increase within three-months of beginning to take the drug.
Since the risks of Invokana users suffering bone fractures came to light, the FDA has called for warning labels of the product to be updated with information regarding the effects Invokana use can have on a patient’s bones.
These warnings came too late for some Invokana users, and many of those victims have chosen to file Invokana® injury lawsuits seeking compensation for their losses.
At Ferrer, Poirot & Wansbrough, we believe in holding the pharmaceutical industry accountable for the safety of the products they release to the market, which is why we’re hopeful resolutions to the lawsuits that have been filed in connection to Invokana drug injuries can bring peace to those who were allegedly harmed by the medication.